DAFNA Capital Management’s Minerva Neurosciences NERV Stock Holding History

DAFNA Capital Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,511	Closed	-$284K	–	89
2019 Q1	$284K	Buy	4,511 +1,250	+38%	+$75.1K	0.12%	72
2018 Q4	$176K	Sell	3,261 -102	-3%	-$7.47K	0.09%	77
2018 Q3	$338K	Sell	3,363 -12,996	-79%	-$977K	0.14%	68
2018 Q2	$1.08M	Sell	16,359 -5,028	-24%	-$305K	0.51%	49
2018 Q1	$1.07M	Hold	21,387	–	–	0.52%	52
2017 Q4	$1.03M	Hold	21,387	–	–	0.56%	51
2017 Q3	$1.3M	Sell	21,387 -13,153	-38%	-$754K	0.81%	38
2017 Q2	$2.44M	Buy	34,540 +21,875	+173%	+$1.42M	1.74%	16
2017 Q1	$821K	Buy	+12,665	New	+$984K	0.69%	42
2016 Q4	–	Sell	-4,138	Closed	-$467K	–	69
2016 Q3	$467K	Sell	4,138 -5,875	-59%	-$570K	0.33%	58
2016 Q2	$818K	Buy	+10,013	New	+$637K	0.65%	46
2015 Q2	–	Sell	-12,665	Closed	-$507K	–	80
2015 Q1	$507K	Buy	+12,665	New	+$524K	0.39%	48

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAFNA Capital Management's NERV Position: Q2 2019 in Review

DAFNA Capital Management sold out of Minerva Neurosciences (NERV) in Q2 2019, closing a stake of 4,511 shares — an estimated $284K sold.

DAFNA Capital Management first reported a position in NERV in Q1 2015 and held it in 12 quarters. The position peaked at $2.44M in Q2 2017. 85 funds tracked by Wall St. Rank hold NERV as of Q2 2019.

DAFNA Capital Management reported no remaining Minerva Neurosciences position as of Q2 2019 after selling out during the quarter.
DAFNA Capital Management sold 4,511 Minerva Neurosciences shares in Q2 2019, an estimated $284K.
DAFNA Capital Management first reported a position in Minerva Neurosciences in Q1 2015 and held it in 12 quarters.
DAFNA Capital Management's Minerva Neurosciences position peaked at $2.44M in Q2 2017.
85 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2019.

Based on DAFNA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.